Back To: Home

January 19-23, 2015
PepTalk - San Diego, CA

February 7-11, 2015
SLAS2015 - Washington, DC

More Events

Zealand Pharma inks license agreement with Abbott
June 2012

COPENHAGEN—Zealand Pharma recently announced the signing of a license agreement with Abbott for the development and commercialization of AP214, a first-in-class melanocortin peptide agonist, invented and developed by Action Pharma AS, and modified by using Zealand Pharma's SIP-technology. The new agreement replaces its predecessor, established between Zealand Pharma and Action Pharma for the same compound. Abbott signed an agreement to acquire the rights to AP214 from Action Pharma, triggering a payment of $11 million to Zealand from Action Pharma. Per the agreement, Abbott will assume full responsibility for further development and commercialization of AP214 for the prevention of acute kidney injury and other relevant indications, while Zealand Pharma will be entitled to a low single-digit royalty on Abbott's future sales of AP214.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.